IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Ap	oplication of: Louis Johan Wagenaar))			
Applica	tion No: 10/615,592) Art Unit: 1615			
Filed: July 8, 2003		Confirmation No.: 8286			
For:	PROCEDURE AND COMPOSITION OF TREATMENT AND/OR CARE OF THE EYE	Examiner: Azpuru, Carlos			

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant hereby brings to the Examiner's attention the references listed on the accompanying form PTO-1449. Copies of all listed references are attached.

Reference D0 is a copy of an opposition filed by Novartis AG against European patent EP1347787B1 (Reference D00), which corresponds to the above-referenced U.S. patent application but includes different claims from those pending in the abovereferenced U.S. patent application.

References D0 and D00 do not constitute prior art. Reference D0 is submitted to provide an English explanation of the relevance, if any, of German language references D1, D2, D3, D4, D7, and D8, and reference D00 is submitted to provide the claims against which the English exculantion is directed.

References D4, D7, and D8 are directly addressed in Reference D0 at pages 12-13 (D4) and 17-20 (D7 and D8). Reference D4 is a datasheet for a product named SICCAPROTECT Augentropfien. German language references D1-D3, which were filed as part of another opposition against EP1347787, also concern SICCAPROTECT products, so a discussion of their relevance, if any, is also provided by D

PATENTS Attorney Docket No. BAY-001.01

English translations are attached to each of the German language references. Either the entire reference is translated, or portions which were relied upon in the opposition proceedings, and hence caused the references to be listed here, are translated.

Please charge any required fees to Deposit Account No. 06-1448, ref. BAY-

001.01

Respectfully submitted.

Date: January 23, 2007 Customer No: 25181 Patent Group

Foley Hoag LLP 155 Seaport Blvd.

Boston, MA 02210-2600

/SCOTT E. KAMHOLZ/ Scott E. Kamholz, Reg. No. 48,543 Attorney for Applicant

Tel. No. (617) 832-1746 Fax. No. (617) 832-7000

n PTO-1409 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets of necessary)			BAY-001.01	Dockst Number (Options) BAY-001.01 Applicant		Short Page 1 of 10/615,592				
			Filing Date July 8, 2003			Group Art Unit 1615				
			FOREIGN P	ATENT DOCUME	NTS					
	DO	CUMENT NUMBER	DATE	ATE COUNTRY		SUBCLASS	Translation YES NO			
	D00	EP1347787B1 Ap	r. 13, 2005	EPO			100	1.0		
		OTHER	DOCUMENTS		(Including Autho	er, Title, Date, Pertin	em Pases E	nc.)		
	Do	Opposition against EP134/T87 filed by Novartis AG, filed 13 January 2006 (submitted to provide English-language explanation of relevance, if any, of the following German-language references).								
	DI	Fachinformation ("Technical Information") SICCAPROTECT*, Ursapharm Arzneimittel GmbH, January 1990. Full English translation attached.								
	D2	"producta ophthalmica sterilisata," Ursapharm, January 1988. Partial translation English of page 4 attached.								
	D3	"SICCAPROTECT*," attached.	Ursapharm Arzne	imittel GmbH & Co. F	KG, September 200	0. Full English t	anslation			
	D4	Fachinformation zur Substanzgruppe Kuenstliche Tracen ("Technical information on Artifical Tear Substances"), including Datasheet for Siccaprotect® Augentropfen ("Eye drops"), allegedly available commercially since 1984. English translation of Siccaprotect datasheet attack of tasks.								
	D7	Ophthalmike, 4 th edition, pp. 185-186 (1990). English translation of "Dexpantheol" entry spanning pp. 185-186 attached.						86		
	-	Ophthalmike, 4 th edition, pp. 509-518 (1990). English translation of Section 3.10.3 "Wechselwirkungen zwischen Kontaklinsen, Kontaklinsenpflegemitteln und Arzneimitteln ("Interaction between Contact Lenses, Contact-Lens Cleaners and Medications") pp. 513-514 attacks.								
	D8	Kontaktlinsen, Kontakt			Interaction between	Contact Lenses	, Contact-	Lons		

For